RenBio Information

RenBio is a biotechnology company focused on advancing the delivery of first-in-class and best-in-class ultra long-acting DNA therapeutics to humans. Utilizing its proprietary nucleic acid platform, MYO Technology, RenBio aims to deliver DNA medicines as a next-generation alternative to traditional antibody and protein therapeutics. Based on a patent protected electroporation technique, the MYO Technology platform enables the delivery of naked, proprietary plasmid DNA encoding antibody and protein therapeutics via direct intramuscular injection for sustained production in the body. RenBio’s internal, preclinical development programs illustrate the broad utility of MYO Technology in enabling the long-term, in vivo production of antibodies (antiviral antibodies, anti-IL-23 antibodies) and therapeutic proteins (G-CSF, GLP-1R agonists). RenBio is backed by the Bill & Melinda Gates Foundation, DARPA, BARDA, Wellcome Trust, and a syndicate of private investors, and is headquartered in New York City.